Generics May Seek Correction Of Overly Broad Use Codes

In Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S, 132 S. Ct. 1670 (April 17, 2012) [enhanced version available to lexis.com subscribers], the Supreme Court unanimously held that a generic drug company may use a counterclaim provision of the Hatch-Waxman Act to seek correction of an overly broad use code submitted by a brand drug company in connection with patents listed in the FDA Orange Book. In this Analysis, Dianna Goldenson El Hioum addresses this issue and its implications.

Sign in with your Lexis.com ID to access the full text of this article (approx. 4 pages).

Click here to order the full text of this article if you do not have a Lexis.com ID

....

Sign in with your Lexis.com ID to access Patent Law resources on Lexis.com or any of these Mathew Bender Patent Law publications. 

Click here to order Patent Law treatises/resources and Mathew Bender publications. 

LexisNexis Publications:

View the LexisNexis Catalog of Legal and Professional Publications

LexisNexis eBooks

Click here for a list of available LexisNexis eBooks.

Click here to learn more about LexisNexis eBooks.

For more information about LexisNexis products and solutions connect with us through our corporate site.